Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastim
Not Applicable
Recruiting
- Conditions
- nresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000028055
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe myelosuppression 2)Active infection (except viral hepatitis) 3)Serious complications (organ failure, or active peptic ulcer etc) 4)Severe diarrhea 5)Intestinal pneumonitis or pulmonary fibrosis 6)Treatment-resistant ascites or pleural effusion 7)Brain or meningeal metastasis 8)Pregnancy or breast-feeding 9)Any contraindication for FOLFIRINOX 10)Severe complication by administration of pegfilgrastim 11)Severe mental disorder, or central nervous system disorders 12)Contraindication for dynamic CT/MRI 13)Inappropriate for this study judged by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of febrile neutropenia during the first 2 cycles of FOLFIRINOX
- Secondary Outcome Measures
Name Time Method